HEP 1732

Drug Profile

HEP 1732

Alternative Names: HEP-1732

Latest Information Update: 08 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TGV-Laboratories
  • Class Anti-infectives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C
  • Research Liver cirrhosis

Most Recent Events

  • 01 Apr 2015 Early research in Hepatitis C in USA (PO)
  • 01 Apr 2015 Early research in Cirrhosis in USA (PO)
  • 01 Apr 2015 Phase-II clinical trials in Hepatitis C in Russia (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top